[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psoriasis-pso\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psoriasis-pso":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,42,64,87,122,143,172,193,225,250,278,299,325,346,377,402,427,450,475,537,559,579,603,629],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642273","effects-of-different-secukinumab-maintenance-regimens-on-long-term-outcomes-in-patients-with-psoriasis-100642273",false,"NCT07642544","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.\n* Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.\n* Achieved PASI 75 response at the end of the induction period.\n* Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.\n* Complete electronic medical record data available for extraction.\n\nExclusion Criteria:\n\n* Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.\n* Irregular maintenance treatment pattern, or substantial missing data.\n* Use of other targeted biologic agents or small molecule drugs during the maintenance period.\n* Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.\n* Participation in other interventional clinical trials that may confound efficacy assessment.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.",[24,25],"Psoriasis","Psoriasis (PsO)",[27,28],"psoriasis","secukinumab","NOT_YET_RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":20},"2026-06-01",{"date":37,"type":20},"2027-03-01",{"name":39,"class":40},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100643727","phase-4-efficacy-of-topical-tapinarof-versus-betamethasone-in-the-treatment-of-plaque-psoriasis-100643727","NCT07635043","Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis","Inclusion Criteria:\n\n* Age 18 years-65 years\n* Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)\n* Disease duration of at least 6 months\n* Willing and able to provide written informed consent\n* Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)\n\nExclusion Criteria:\n\n* Severe psoriasis (BSA \\>20% or requiring systemic therapy)\n* Pregnant and lactating mothers\n* Known hypersensitivity to Tapinarof or any of its excipients\n* Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis\n* Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment\n* History of malignancy or current active infection\n* Known hypersensitivity to betamethasone or Tapinarof\n* Use of powerful topical corticosteroids within two weeks previously","65 Years",{"count":19,"type":20},"INTERVENTIONAL",[52],"PHASE4","To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad",[25],"2026-06-03",{"date":30,"type":33},{"date":58,"type":20},"2026-08-01",{"date":60,"type":20},"2026-11-30",{"name":62,"class":63},"Pakistan Institute of Medical Sciences","OTHER_GOV",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":74,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100643502","global-healthcare-study-on-psoriasis-100643502","NCT07634016","Global Healthcare Study on Psoriasis","GHSP","Inclusion Criteria:\n\n* Signed General Consent Form, or equivalent document\n* Confirmed diagnosis of Psoriasis\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Datasets with ambiguous or unclear diagnosis.","14 Years",{"count":73,"type":20},9600,"5 Years","The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.",[25],"RECRUITING","2026-06-02",{"date":80,"type":33},"2026-06-08",{"date":82,"type":33},"2025-01-01",{"date":84,"type":20},"2029-12-31",{"name":86,"class":40},"Julia Tatjana Maul",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":50,"phases":96,"briefSummary":98,"conditions":99,"keywords":105,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100627972","phase-1-study-of-s-4321-in-participants-with-an-autoimmune-or-immune-mediated-disease-100627972","NCT07455578","Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease","Phase 1b, Open-Label, Exploratory Biomarker Basket Study of S-4321 in Participants With an Autoimmune or Immune-Mediated Disease","All Participants Major Inclusion Criteria:\n\n1. Adult males and females, 18 to 75 years of age (inclusive)\n2. Body mass index (BMI) ≥18.0 and \\\u003C40.0 kg\u002Fm2 with a minimum body weight of 45 kg\n3. Use of adequate contraception for both males and females. Female volunteers must be of nonchildbearing potential or if of childbearing potential, must have a negative pregnancy test.\n\nAll Participants Major Exclusion Criteria:\n\n1. Have received a PD-1 agonist, immune checkpoint agonist, immune checkpoint inhibitor, anti-CD19 or anti-CD20 agents, cell therapy, B cell modulating agents, alkylating agents, or any other immune cell depleting therapy.\n2. Have received azathioprine, cyclosporine, mycophenolate mofetil, or tacrolimus within 4 weeks\n3. Unable or unwilling to discontinue a prohibited medication\n4. Presence of clinically relevant immunosuppression\n5. Current infection or history of severe infection\n6. Any history of malignant disease, with some exceptions\n\nMajor inclusion\u002Fexclusion for each autoimmune or immune-mediated disease:\n\nFor RA:\n\n1. Confirmed diagnosis of moderate to severe active RA by the American College of Rheumatology (ACR) 2010\u002FEuropean League Against Rheumatism (EULAR) criteria for at least 3 months prior to the Screening 1 visit, and:\n\n   1. ≥6 swollen joint count based on 66 joint count\n   2. ≥6 tender joint count based on 68 joint count\n   3. Seropositive for RF and\u002For ACPA\n   4. Elevated hsCRP ≥1.2 times greater than the ULN\n   5. Does not have Class IV RA according to ACR revised criteria\n2. Inadequate response to, or loss of response, or intolerance to:\n\n   1. \\>1 conventional synthetic DMARD after 3 months of therapy OR\n   2. \\>1 biologic DMARD\u002Ftargeted synthetic DMARD after 3 months of therapy\n   3. Has not failed 3 or more bDMARDs and\u002For tsDMARDs\n\nFor PsA:\n\n1. Confirmed diagnosis of adult-onset PsA classified by the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 3 months prior to the Screening 1 visit, with all of the following:\n\n   1. Active PsO defined by at least 1 psoriasis lesion\n   2. Active disease defined by \\>3 swollen joints and \\>3 tender joints using the 76\u002F78 swollen and tender joint count\n2. Received standard doses of NSAIDs for \\>4 weeks or csDMARDs for \\>3 months and has been on a stable dose for \\>8 weeks, or participant has intolerance to NSAIDs or DMARDs\n3. Participants may be TNF inhibitor therapy naïve or may have received 1 prior TNF inhibitor\n4. Has not had inadequate response or intolerance to 2 or more bDMARDs or csDMARDs\n\nFor PsO:\n\n1. Confirmed diagnosis of moderate to severe plaque PsO for at least 6 months, with all of the following:\n\n   1. Psoriasis Area and Severity Index (PASI) \\>12 points\n   2. Static Physician's Global Assessment (sPGA) \\>3 points\n   3. Body surface area (BSA) of PsO involvement \\>10%\n2. Cannot have a clinically significant flare within 12 weeks\n3. Does not have history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis\n4. Has not had inadequate response to more than 2 prior bDMARDs\n\nFor CLE (with or without systemic manifestations):\n\n1. Histologically confirmed diagnosis of CLE with or without systemic manifestations for at least 6 months\n2. Has active skin manifestations as measured by CLASI-A \\>10 or CLASI-A \\>8, if there is no alopecia or mucous membrane lesions\n3. Participant must have an active CLE lesion despite an adequate trial of antimalarial treatment for at least 6 months.\n4. Cannot have active lupus nephritis or moderate-to-severe or chronic kidney disease with eGFR \\\u003C45 mL\u002Fmin\u002F1.73m2\n5. Cannot have active neuropsychiatric SLE\n\nFor AD:\n\n1. Confirmed diagnosis of AD as defined by the American Academy of Dermatology: Guidelines of Care for the Management of Atopic Dermatitis for at least 12 months\n\n   1. Eczema Area and Severity Index (EASI) \\>16\n   2. Validated Investigator Global Assessment (vIGA-AD) \\>3\n   3. BSA of AD involvement \\>10%\n   4. PP-NRS) \\>4 (average of daily scores) during the 7 days prior to dosing\n2. Inadequate response to existing topical medications within 6 months or has a history of intolerance to topical therapy as defined by at least 1 of the following:\n\n   1. Inability to achieve good disease control after use TCS for at least 4 weeks\n   2. Documented history of clinically significant AEs with the use of TCS\n   3. Failed systemic therapies intended to treat AD within 6 months\n\nAdditional inclusion\u002Fexclusion criteria will apply.","75 Years",{"count":5,"type":20},[97],"PHASE1","This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).",[100,101,102,25,103,104],"Autoimmune Diseases","Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Cutaneous Lupus Erythematosus (CLE)","Atopic Dermatitis (AD)",[106,107,108,109,110,104,25,102,103,111],"Autoimmune","Immune-mediated","S-4321","Seismic Therapeutic","Rheumatoid Arthritis","Cutaneous Lupus","2026-05-28",{"date":35,"type":33},{"date":115,"type":20},"2026-06",{"date":117,"type":20},"2027-09",{"name":119,"class":120},"Seismic Therapeutic AU Pty Ltd","INDUSTRY",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100639246","inflammation-digital-biomarkers-validation-study-100639246","NCT07594054","Inflammation Digital Biomarkers Validation Study","IDBV: Inflammation Digital Biomarker Validation Study","IDBV","Inclusion Criteria:\n\nPreviously consented to take part in the HPOS study and have agreed to be contacted for future ethically approved studies.\n\nAdults with psoriasis with no diagnosis of PsA.\n\nHave a compatible smartphone\n\nHave a good command of local language\n\nExclusion Criteria:\n\nParticipants not consented into the HPOS study\n\nDo not have use of a compatible smartphone\n\nAre not willing to use the smartphone app.\n\nAdults with a pre-existing diagnosis of PsA",{"count":131,"type":20},3458,"HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease. As part of the project, the HIPPOCRATES Prospective Observational Study (HPOS) is a study of patients with psoriasis which is recruiting across Europe. The study is led by a research team at University of Oxford and supported by a team at University College Dublin. This current study aims to identify people with psoriasis who are at risk of developing psoriatic arthritis. Up to one-third of patients with psoriasis will develop a related arthritis causing inflammation in the joints and tendons. The investigators want to identify which patients will develop arthritis with the long-term and ambitious aim of trying to prevent the development of arthritis before it occurs. The HPOS study is currently recruiting\u002Fapproaching adults with psoriasis and asking study participants to complete questionnaires every 6 months via a dedicated study website. The questionnaires include a 'screening questionnaire' to try to identify arthritis.\n\nAdults with psoriasis but without a pre-existing diagnosis of PsA are currently being recruited via clinics, national and international patient support organisations including those under the umbrella of EUROPSO, and media campaigns. Participants are recruited across Europe in the following countries: UK, Ireland, Italy, France, Spain, Denmark, Germany, Belgium, Netherlands, Sweden, Portugal, Greece, Norway, Switzerland, Poland and Romania. The University of Oxford is the sponsor for the study across all countries, but local regulations will be followed, and local ethical approval has been sought for each different country. Data is requested from participants every 6 months and they will be prompted by email.\n\nLikewise, the iPROLEPSIS consortium is a Horizon Europe funded consortium investigating digital biomarkers in PsA. In 2024, the consortium launched a study recruiting 600 patients with PsA across 4 counties, utilising digital biomarkers to identify disease flares. This includes the use of smartwatches, a mobile phone app and active video tests. This will allow us to develop algorithms to identify active disease.\n\nSimilar approaches are proposed for a study called the Inflammation Digital Biomarkers Study (IDBV) which will try to identify the onset of PsA in people living with psoriasis. Patients in HPOS who have given consent to be contacted about additional studies, will be offered the opportunity to join this study. They will complete an additional consent form and will download the miPROLEPSIS lite app to their mobile phone.\n\nThe Study app will passively collect data from the user's phone; participants do not need to perform any specific tasks apart from some initial configuration steps like logging in and connecting their wearables (Connecting a wearable is optional).\n\nThe investigators intend to run IDBV as a sub-study in HPOS and invite participants enrolled into the HPOS study who do not have a diagnosis of PsA.",[134,25],"Psoriatic Arthritis","2026-05-20",{"date":137,"type":33},"2026-05-22",{"date":115,"type":20},{"date":140,"type":20},"2027-12",{"name":142,"class":40},"University of Oxford",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100627415","psoriasis-comorbidities-at-hospital-caldern-guardia-100627415","NCT07448337","Psoriasis Comorbidities at Hospital Calderón Guardia","Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025","Inclusion Criteria:\n\n* Patients evaluated in outpatient clinics during the period 2024-2025.\n* Patients receiving systemic therapy and\u002For phototherapy.\n* Patients aged 12 years or older, of any sex.\n* Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.\n* At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.\n* Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.\n\nExclusion Criteria:\n\n* Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.\n* Patients managed exclusively with topical therapies.\n* Duplicate or inconsistent records, preventing accurate patient classification.\n* Cutaneous conditions not compatible with psoriasis.","12 Years",{"count":152,"type":20},350,"The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics and severity profiles of psoriasis patients?\n\nWhat treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?\n\nPatients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.",[24,155,25,156],"Psoriasis Arthritis","Psoriasis Patients",[158,159,24,160,161,162],"Comorbidities","Costa Rica","Real-world data","Disease severity","Epidemiology","2026-04-02",{"date":165,"type":33},"2026-04-08",{"date":167,"type":20},"2026-05",{"date":169,"type":20},"2027-05",{"name":171,"class":63},"Caja Costarricense de Seguro Social",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":179,"targetDuration":74,"studyType":21,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100627420","costa-rican-registry-of-il-23-inhibitors-in-psoriatic-disease-100627420","NCT07448402","Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and\u002For psoriatic arthritis based on rheumatologic criteria.\n* Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).\n* Treated within participating Costa Rican public health centers.\n* Availability of sufficient clinical records to complete registry data (history, follow-up, labs).\n* Age ≥12 years, any sex.\n\nExclusion Criteria:\n\n* None specified (all patients meeting inclusion criteria are eligible).",{"count":180,"type":20},50,"The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and\u002For psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:\n\n* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?\n* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?\n* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA\u002FBASDAI) and adverse-event reporting through a national registry.",[24,155,25],[24,184,185,159],"IL-23","Registry","2026-03-06",{"date":188,"type":33},"2026-03-09",{"date":167,"type":20},{"date":191,"type":20},"2031-05",{"name":171,"class":63},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":50,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":41},"100623850","phase-4-effects-of-semaglutide-on-clinical-outcomes-and-metabolic-inflammation-in-psoriasis-100623850","NCT07401992","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","SEMAPSO","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of randomization.\n* Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%.\n* Body mass index (BMI) ≥25 kg\u002Fm², consistent with overweight or obesity.\n* Participants with or without type 2 diabetes mellitus.\n* Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline.\n* No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization.\n* No use of biologic therapies for at least 3 months prior to randomization.\n\nExclusion Criteria:\n\n* Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis.\n* Pregnancy or breastfeeding at the time of screening or enrollment.\n* Insulin-dependent diabetes mellitus or current use of sulfonylureas.\n* Active malignancy at the time of screening.\n* History of thyroid neoplasia.\n* Presence of autoimmune diseases.\n* Use of systemic therapies within 8 weeks prior to randomization.\n* Use of biologic therapies within 3 months prior to randomization.\n* Renal insufficiency.\n* Heart failure.\n* Hepatic insufficiency.\n* History of pancreatitis.\n* Current treatment with other GLP-1 receptor agonists.\n* History of inflammatory bowel disease.\n* Known allergy to starch.",{"count":202,"type":20},62,[52],"This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid\u002Fcalcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight\u002Fobesity and\u002For type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid\u002Fcalcipotriol or placebo plus topical corticosteroid\u002Fcalcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.",[25,206,207],"Obesity & Overweight","Diabetes Mellitus - Type 2",[209,27,210,211,212,213,214,215],"clinical trial","dermatology","semaglutide","GLP-1","obesity","overweight","diabetes","2026-02-03",{"date":218,"type":33},"2026-02-11",{"date":220,"type":33},"2026-01-15",{"date":222,"type":20},"2027-02-28",{"name":224,"class":40},"Hospital Universitario Dr. Jose E. Gonzalez",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":50,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":41},"100622966","the-effects-of-audio-based-therapy-on-anxiety-in-psoriasis-100622966","NCT07390487","The Effects of Audio-Based Therapy on Anxiety in Psoriasis","PsOUND-PSO","Inclusion Criteria:\n\n* Age ≥18 years\n* Self-reported dermatologist-diagnosed psoriasis\n* GAD 2-Item Score ≥1 at screening\n* Ability to consent and complete pre- and post-intervention surveys.\n* Internet access and the ability to use a computer\u002Fsmartphone with headphones for a single 23-30 minute session at home.\n\nExclusion Criteria:\n\n* Severe hearing impairment precluding headphone listening\n* Any condition requiring strict sound avoidance (such as seizure\u002Fepilepsy, major head trauma, severe sound-triggered migraine) that would make participation unsafe.\n* Other diagnoses that in the investigator's judgment preclude safe participation or interfere with anxiety or psoriasis evaluation.",{"count":19,"type":20},[234],"NA","Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.",[25,237],"Anxiety",[239,240,241],"Surveys and Questionnaires","Acoustic Stimulation","Complementary Therapies","2026-01-29",{"date":244,"type":33},"2026-02-05",{"date":246,"type":20},"2026-02",{"date":140,"type":20},{"name":249,"class":40},"University of California, San Francisco",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100621449","impact-of-tildrakizumab-on-patient-reported-outcomes-in-patients-with-moderate-to-severe-psoriasis-in-canada-100621449","NCT07370766","Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada","A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada","PRO\u002FPsO","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \\>\u002F=3%).\n3. Candidate for phototherapy and\u002For systemic therapy.\n4. Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.\n\n   a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.\n5. Must be able to read, understand, and communicate in English.\n6. Must be willing to participate in the study and capable to provide informed consent\n7. Able to comply with all study procedures and attend all study visits\n\nExclusion Criteria:\n\n1. Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.\n2. Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)\n3. Diagnosis of only palmoplantar psoriasis\n4. Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments\n5. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.\n6. Prior (within 30 days) or actively participating in other interventional clinical trial(s).\n7. Unable or unwilling to comply with study procedures including completing questionnaire.\n8. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results",{"count":259,"type":20},80,"This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above.\n\nThe real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above.\n\nThe findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.",[25,262],"Moderate to Severe Psoriasis",[27,264,265,266,267],"moderate to severe psoriasis","Fitzpatrick scale","tildrakizumab","patient reported outcomes","2026-01-20",{"date":270,"type":33},"2026-01-27",{"date":272,"type":33},"2025-11-25",{"date":274,"type":20},"2027-05-30",{"name":276,"class":40},"Chronicle Academy",6,{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":284,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":285,"targetDuration":287,"studyType":21,"phases":4,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":41},"100619963","research-on-the-extraction-of-tongue-and-facial-diagnosis-features-of-psoriasis-vulgaris-in-traditional-chinese-medicine-and-its-correlation-with-laboratory-indicators-100619963","NCT07351448","Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators","Inclusion Criteria:\n\n* Inclusion criteria for the non-psoriasis subjects: (1) Those who do not meet the Western medical diagnostic criteria for psoriasis; （2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form; Inclusion criteria for the psoriasis blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood stasis syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nInclusion criteria for the psoriasis non-blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood heat syndrome\u002Fblood dryness syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Due to various reasons, the collected tongue and facial images may be unclear or cannot be successfully monitored and analyzed; (2) For those subjects whose facial makeup or tongue coating is applied, the information obtained from tongue and facial diagnosis may be inaccurate.",true,{"count":286,"type":20},450,"2 Weeks","Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients. Its clinical features include erythema, papules, covered with varying scales, a long course of disease, and recurrent attacks. According to traditional Chinese medicine, psoriasis is mainly characterized by blood heat syndrome, blood stasis syndrome and blood dryness syndrome, accounting for more than 90% of all syndrome types. The TCM syndrome differentiation and treatment of psoriasis also attach great importance to the transformation and evolution of TCM syndrome types. For instance, the three syndrome types of blood heat syndrome, blood stasis syndrome and blood dryness syndrome are not static and can transform into each other. For example, blood heat syndrome can develop into blood dryness syndrome as the disease progresses, blood dryness syndrome can transform into blood stasis syndrome, and blood stasis syndrome can also transform into blood heat syndrome or blood dryness syndrome. Observation is an important diagnostic method in traditional Chinese medicine. The images of tongue and face diagnosis contain a lot of important clinical information. They can objectively reflect the prosperity and decline of qi and blood in the human body, the nature of diseases, the depth of the lesion location, the prognosis of the disease, and can also reflect the physiological and pathological changes of the body. In recent years, significant progress has been made in the research of digital and intelligent technologies for tongue and facial diagnosis. Introducing objective indicators such as tongue diagnosis, facial diagnosis and pulse diagnosis into the evaluation research of diseases has become a hot topic. This project, by analyzing the clinical tongue and facial image data of patients with psoriasis vulgaris and combining it with clinical laboratory indicators, fuses and analyzes the characteristic parameters of patients' tongue and facial diagnosis with blood biochemical indicators, metabolomics and other data. This is helpful to reveal the disease occurrence pattern of patients with blood stasis type psoriasis and construct a diagnostic model for blood stasis syndrome of psoriasis. At the same time, it provides a powerful decision support tool for clinical practice and also helps deepen our understanding of the complex process of the occurrence of blood stasis type psoriasis, thereby providing a solid scientific basis for formulating precise diagnostic and treatment strategies.",[25,290,291],"Traditional Chinese Medicine (TCM)","Diagnosis","2026-01-12",{"date":268,"type":33},{"date":268,"type":20},{"date":296,"type":20},"2027-09-30",{"name":298,"class":40},"Shanghai Yueyang Integrated Medicine Hospital",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":50,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100591586","phase-1-safety-and-pharmacokinetics-of-lpx-ti641-in-atopic-dermatitis-and-psoriasis-100591586","NCT06982352","Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis","Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis","Inclusion Criteria:\n\n1. Subject has signed an Informed Consent Form (ICF) prior to any study-specific procedures being performed\n2. ≥ 18 years old, irrespective of their race and ethnicity.\n3. Body Mass Index (BMI) 18.0-40.0 kg\u002Fm2, inclusive, at screening.\n4. Participants are willing and able to adhere to study protocol requirements and restrictions including but not limited to scheduled outpatient visits, inpatient stay, laboratory tests, and 12-lead ECGs.\n5. The subject must be judged to be in good health by the investigator to participate in the study, based on clinical evaluations, including laboratory safety tests, medical history, physical examination, vital signs and 12-lead ECG completed at the screening visit and prior to the first dose of study drug.\n6. Female subject is postmenopausal (at least 1 year; to be confirmed by FSH if less than 2 years since last menstrual period), permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or if of childbearing potential and engaged in sexual activity that can result in pregnancy must agree to use any two of the highly effective contraception methods listed below. Male participants with a partner of childbearing potential must also agree to use any two of the highly effective contraception methods listed below between them and their partner. This criterion must be followed from screening visit to 6 weeks after the last dose in females and for 90 days after the last dose for males.\n\n   The following applies to all female participants with childbearing potential and female partners of male participants enrolled in the study.\n   1. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.\n   2. Intrauterine device.\n   3. Intrauterine hormone-releasing system.\n   4. Bilateral tubal occlusion.\n   5. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:\n   6. Oral\n   7. Intravaginal\n   8. Transdermal\n   9. Injectable\n   10. Progestogen-only hormone contraception (oral or injectable) associated with inhibition of ovulation.\n   11. Vasectomized partner\n   12. Sexual abstinence -this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated about the duration of the study and the preferred and usual lifestyle of the participant.\n   13. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods)\n\n       The following applies to all male participants in the study:\n   14. Sexual abstinence- this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence must be evaluated for the study and the participant's preferred and usual lifestyle.\n   15. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).\n   16. Vasectomy\n7. Negative serum B-human chorionic gonadotropin test at screening (for all females) and negative urine pregnancy at randomization (Day 1) (females of childbearing potential) prior to administration of investigational product.\n\n   For Atopic Dermatitis Cohort:\n8. Diagnosis of AD at least 12 months prior to screening, as defined by the American Academy of Dermatology: Guidelines of care for the management of atopic dermatitis (Eichenfield 2014):\n\n   1. EASI score ≥ 16 at Screening and baseline (Day 0)\n   2. vIGA score of ≥3 at screening and baseline (Day 0)\n   3. ≥10% of body surface area (BSA) involvement at screening and baseline (Day 0)\n   4. Peak pruritis NRS≥4 (average score of daily scores 7 days before Day 0)\n9. History, documented by a physician and\u002For investigator, of inadequate response to existing topical medications within 6 months preceding screening, or history of intolerance to topical therapy as defined by at least 1 of the following:\n\n   1. Inability to achieve good disease control defined as mild disease or better (e.g., IGA≤2) after use of at least a medium potency topical corticosteroid (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (e.g. 14 days for super potent TCS), whichever is shorter (Note: a TCS may be used with or without topical calcineurin inhibitors \\[TCNIs\\])\n   2. Documented history of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment\n   3. Failed systemic therapies intended to treat AD within 6 months preceding screening (will be considered as having inadequate response to topical therapy)\n10. Documented history of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment\n\n    For Plaque Psoriasis Cohort:\n11. Confirmed diagnosis of plaque psoriasis for at least 6 months prior to baseline (Day 0)\n12. Plaque psoriasis involving ≥10% body surface area (BSA) in the affected skin other than the face and scalp at screening and baseline (Day 0)\n13. Static Physician's Global Assessment (sPGA) score ≥3 at screening and baseline (Day 0)\n14. PASI score of ≥12 at screening and baseline (Day 0)\n15. Subject must be candidate for phototherapy or systemic therapy\n16. Subject had no significant flare in psoriasis for at least 3 months before screening\n\nExclusion Criteria:\n\n1. History of clinically significant medical conditions or any other reason that in the opinion of the PI would interfere with subject's participation in this study\n2. History of clinically significant drug or alcohol abuse per the PI's opinion within the last 6 months.\n3. Pregnant or lactating women or women currently undergoing infertility treatments or women who intend to become pregnant during the time of study or for 6 weeks after last dose.\n4. Presence of skin comorbidities that would interfere with study assessment or response to treatment\n5. Any known history of malignancy within 5 years other than completely treated non-metastatic basal cell carcinomas or squamous cell carcinomas of the skin or localized carcinoma in situ of the cervix.\n6. Patients who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics\n7. Symptomatic herpes zoster within 3 months of screening\n8. For the plaque psoriasis cohort,\n\n   1. Unstable forms of PsO (acute guttate PsO, psoriatic erythroderma, generalized pustular PsO, or other unstable form as judged by the investigator), or drug-induced psoriasis.\n   2. History of any non-PsO disease that required treatment with oral or parenteral corticosteroids for more than 2 weeks within the past 24 weeks prior to signing the informed consent form (ICF)\n9. Receipt of an investigational therapy less than 3 months or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study\n10. Use of the following topical medications\u002Femollients which could affect assessment of disease activity for at least 2 weeks prior to baseline (Day 0) and throughout the study:\n\n    1. Topical corticosteroids or topical immune modulators (e.g. tacrolimus or pimecrolimus)\n    2. Topical phosphodiesterase type 4 (PDE 4) inhibitor or JAK inhibitors or aryl hydrocarbon receptor agonists\n    3. Topical or systemic antihistamines\n    4. Use of emollients.\n11. Receipt of any of the following excluded therapies as per below and throughout the study:\n\n    1. Oral retinoids within 2 weeks of Day 0\n    2. Systemic immunosuppressive\u002Fimmunomodulating therapy (such as but not limited to systemic glucocorticoids, cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, apremilast, or oral JAK inhibiting agents or phototherapy within 4 weeks before screening visit. Stable dose of max 1200ug inhaled budesonide (or equivalent) is allowed.\n    3. Any cell depleting therapy, anti-CD4, anti-CD5, anti-CD3 other than anti-CD20 such as rituximab, ocrelizumab, and ofatumumab. Patients who have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to screening\n12. Biologics dugs including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors within 8 weeks or 5 drug elimination half-lives whichever is longer and throughout the study\n13. Failed biologics due to efficacy including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors\n14. PUVA or UVB phototherapy within 4 weeks prior to Day 0 and throughout the study.\n15. Subject has clinical or laboratory evidence of active or latent tuberculosis (TB) infection at screening as assessed by QuantiFERON-TB-Gold or a purified protein derivative skin test or equivalent (or both if required per local guidelines) and chest X-ray. Chest X-rays taken within 2 months prior to screening may be used instead of during screening if there is documentation showing no evidence of infection or malignancy as read by qualified physician.\n16. Any active or recurrent infection within 1) the past 8 weeks prior to screening requiring IV\u002Fhospitalization or 2) the past 2 weeks prior to screening requiring oral antibiotics.\n17. Laboratory values of the following at the Screening Visit:\n\n    1. Hemoglobin \\\u003C 11 g\u002FdL\n    2. WBC \\\u003C3.5X109\u002FL\n    3. Absolute neutrophil count (ANC) \\\u003C 1500 cells\u002FµL, (or \\\u003C 1200 cells\u002FµL for participants of African descent who are black)\n    4. Aspartate aminotransferase or alanine aminotransferase \\> 2.0 x the upper limit of normal (ULN) or bilirubin \\>= ULN;\n    5. Bilirubin \\> ULN\n    6. Platelets \\\u003C 100,000 cells\u002F\\[mm\\^3\\] (10\\^9\u002FL)\n    7. Clinically significant abnormal screening laboratory results as evaluated by the Investigator\n18. Acutely worsened renal function within past 3 months prior to screening or estimated GFR by CDK-EPI creatinine equation with adjustment for body surface area \\\u003C60ml\u002Fmin.\n19. Subject has any clinically significant finding on 12-lead ECG at screening or admission. NOTE: QTc(F) interval of \\>450 msec in male participants or \\>470 msec in female participants will be the basis for exclusion from the study. ECG may be repeated once for confirmatory purposes if initial values obtained exceed the limits specified.\n20. Subject with positive results for HBsAg (hepatitis B surface antigens) and\u002For HBcAb (Hepatitis B core antibodies) and\u002For HCV Ab (hepatitis C antibodies) confirmed by HCV RNA, and\u002For HIV Ab (human immunodeficiency virus antibodies).\n21. Blood loss of \\>250 mL or donated blood within 56 days or donated plasma within 7 days of screening.\n22. Recent vaccination with live attenuated vaccines such as influenza, MMR, Herpes zoster, varicella, yellow fever, Rotavirus vaccine, etc., or inactivated vaccines such as Hepatitis A, rabies vaccine, etc. 30 days prior to screening visit\n23. Subject has known sensitivity to any of the components of the investigational product.\n24. Subject is investigative site personnel, sponsor personnel, or a member of their immediate families (spouse, parent, child or sibling whether biological or legally adopted).",{"count":307,"type":20},48,[97],"The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.",[104,25],[312,313,314],"phase 1 study","safety","pharmacokinetics","2025-12-18",{"date":317,"type":33},"2025-12-19",{"date":319,"type":33},"2025-06-15",{"date":321,"type":20},"2026-04-15",{"name":323,"class":120},"LAPIX Therapeutics Inc.",3,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":41},"100615873","physician--vs-questionnaire-based-screening-for-psoriatic-arthritis-in-psoriasis-100615873","NCT07298265","Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis","Comparison of a Physician-Based Versus Questionnaire-Based Approach to Identify Patients With a High Probability of Psoriatic Arthritis Among Patients With Psoriasis: A Prospective Multicenter Study","COMPOSITION","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Definite diagnosis of psoriasis.\n3. Written informed consent.\n\nExclusion Criteria:\n\n1. Unable or unwilling to give informed consent or to comply with the protocol.\n2. Previously assessed by a rheumatologist for the presence of PsA, unless new musculoskeletal symptoms have emerged subsequent to the prior evaluation.",{"count":334,"type":20},500,"Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who are usually responsible for the final diagnosis of PsA and treatment of the musculoskeletal manifestations). Previous epidemiological studies suggest that there may still be a significant proportion of undiagnosed PsA patients among those with psoriasis seen by a dermatologist. At the same time, a diagnostic delay of more than 6 months contributes to poor radiological and functional outcomes in PsA patients. Several screening tools \u002F questionnaires (including the Psoriatic Arthritis Screening Evaluation - PASE, the Toronto Psoriatic Arthritis Screen - ToPAS and its further development - TOPAS 2, the Psoriasis Epidemiology Screening Tool - PEST, and the Early Psoriatic Arthritis Screening Questionnaire - EARP) have been developed and validated in the past decades - all relying mostly on symptoms reported by a patient with psoriasis without an evaluation \u002F confirmation of the presence of musculoskeletal symptoms by a dermatologist. The CONTEST study, which compared three screening tools (PASE, ToPAS and PEST) in a secondary care setting, determined that they all had a good probability of detecting PsA (sensitivity of approximately 80%) but had poor specificity (approximately 35%). Further analysis of the results of the above study has identified the most discriminative questions from each of the three questionnaires, including questions about the back and neck, and these items have been combined to create a new single 8-item screening questionnaire (CONTEST). However, a subsequent study demonstrated a similar performance for the CONTEST and the PEST tools. This poor specificity means that screening questionnaires are often not used in practice and raises a risk of overwhelming rheumatology referrals. In a recent survey of GRAPPA members, most of the participants (consisting of dermatologists, rheumatologists, and patient research partners), suggested that a basic evaluation of MSK symptoms by a dermatologist in addition to the patient-reported symptoms (questionnaire) should be part of the screening \u002F referral process. We hypothesize, therefore, that adding a MSK evaluation by dermatologist in the screening process will be able to improve the outcome of the screening and referral process in relation to the PsA detection. In this study, we plan to evaluate the performance of a physician (dermatologist)-based screening and referral strategy as compared to the strategy based on a questionnaire completed by a patient for the detection of patients with a high probability of a diagnosis of PsA among patients with psoriasis. The primary endpoint will be the proportion of patients diagnosed with PsA among patients with psoriasis referred to a rheumatologist. This will be evaluated in the following groups: 1) PEST-positive and dermatologist-negative patients 2) PEST-positive and dermatologist-positive patients 3) PEST-negative and dermatologist-positive patients 4) PEST-negative and dermatologist-negative patients The primary comparison of the proportions of patients diagnosed with PsA (Fisher's exact test) will be done between the dermatologist-negative vs. positive patients among PEST-positive ones (group 1 vs. group 2).",[25,102],"2025-12-17",{"date":339,"type":33},"2025-12-23",{"date":341,"type":33},"2025-09-22",{"date":343,"type":20},"2026-10",{"name":345,"class":40},"Charite University, Berlin, Germany",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":50,"phases":356,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":41},"100610877","phase-2-a-pilot-study-to-assess-how-safe-and-effective-oral-roflumilast-is-for-treating-moderate-to-severe-psoriasis-in-adults-100610877","NCT07233291","A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults","Evaluation of Efficacy and Safety of Oral Roflumilast in Treatment of Moderate to Severe Psoriasis: a Pilot Study","PSOROFLU","Inclusion Criteria:\n\n* Psoriatic patients ≥ 18 years in whom systemic therapy is indicated.\n* Chronic stable plaque psoriasis.\n* Patients who don't use other systemic therapy for psoriasis in the last 2 months (or naïve who didn't use any systemic therapy before).\n* Safe contraception during the study.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.\n* Age \\\u003C18 years.\n* Other concomitant psoriasis systemic treatments such as Acitretin and biologics.\n* Previous systemic treatment of psoriasis in the last 2 months.\n* Patients receiving inducers or inhibitors of cytochromes CYP3A4 and CYP1A.\n* Other systemic diseases other than COPD, especially hepatic impairment.\n* Hypersensitivity to the active substance of roflumilast or to any of its excipients\n* The use of contraception with gestodene and ethinylestradiol\n* Unreliable patients.",{"count":355,"type":20},36,[357],"PHASE2","This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in adults with moderate-to-severe plaque psoriasis. All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12. Secondary outcomes include change in body mass index (BMI) and safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups.",[25],[24,361,362,363,364,365,366,367],"Moderate to severe Psoriasis","Roflumilast","Oral Roflumilast","PDE4 Inhibitor","Plaque Psoriasis","Pilot Study","Adults","2025-11-29",{"date":370,"type":33},"2025-12-02",{"date":372,"type":33},"2025-08-20",{"date":374,"type":20},"2026-02-28",{"name":376,"class":40},"Ahmed Ibrahim",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":385,"targetDuration":4,"studyType":50,"phases":387,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":401},"100561600","phase-2-a-phase-2-study-of-hb0017-in-psoriasis-patients-100561600","NCT06592274","A Phase 2 Study of HB0017 in Psoriasis Patients","A Multicenter, Randomized, Double-blind Phase 2 Clinical Study Evaluating the Efficacy and Safety of Different Administration Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis","HB0017","Inclusion Criteria:\n\n* Male or female subjects aged 18-75 years (inclusive)\n* Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.\n* Psoriasis Area Severity Index (PASI) \\>=12 and body surface area (BSA) affected by PSO \\>=10% and Static Physician Global Assessment (sPGA) score \\>=3.\n* Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator\n* Subjects who are able to use effective contraception from the screening period to 6 months after the last dose\n\nExclusion Criteria:\n\n* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and\u002For guttate psoriasis) at screening or baseline Drug-induced psoriasis\n* Ongoing use of prohibited treatments\n* Any active infection (other than common cold) within 14 days\n* Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization\n* Have previously received any drug that directly targets IL-17 or IL-17 receptor\n* Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \\<28 days; infliximab and adalimumab \\<60 days; golimumab \\< 90 days; anti-IL-12\u002Fanti-IL-23 or anti-IL-23p19 antibody drugs \\<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization\n* A history of inflammatory bowel disease or other serious autoimmune disease\n* Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency",{"count":386,"type":20},200,[357],"This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects",[25],[383,27,391],"longer dose regimen","2025-09-09",{"date":394,"type":33},"2025-09-15",{"date":396,"type":33},"2024-09-30",{"date":398,"type":20},"2026-01-30",{"name":400,"class":120},"Huabo Biopharm Co., Ltd.",18,{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":50,"phases":410,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":41},"100605937","early-phase-1-microbiome-and-clinical-response-to-probiotics-and-methotrexate-in-early-psoriasis-a-pilot-study-100605937","NCT07169019","Microbiome and Clinical Response to Probiotics and Methotrexate in Early Psoriasis: a Pilot Study","Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate: a Pilot Study","Inclusion Criteria:\n\n* Newly diagnosed patients with chronic plaque psoriasis.\n\nExclusion Criteria:\n\n* • Psoriatic patients who used systemic treatments at least 3 months before the study, with the exception of acetritin use, in the last 3 years.\n\n  * Patients who have skin infection or other skin or autoimmune diseases such as SLE, Lichen planus, Dermatomyositis and Vitiligo, by history and examination.\n  * Pregnant or Lactating mothers.\n  * Patients with any contraindication to methotrexate treatment.\n  * Patients who develop any adverse reaction during systemic treatment with methotrexate that necessitates cessation of treatment before the 16th week, such as bone marrow suppression as indicated by CBC, elevated liver enzymes, or severe GIT upset.\n  * Patients with low intellectual capacity, uneducated patients, or patients unable or unwilling to provide daily feedback about their compliance to the provided probiotics treatment.",{"count":5,"type":20},[411],"EARLY_PHASE1","The goal of this clinical trial is to learn if probiotics work to improve the response of psoriatic patients to methotrexate treatment in adults. It will also learn about the beneficial effect of probiotics on the gut microbiota of psoriatic patients treated with methotrexate. The main questions it aims to answer are:\n\nDo probiotics enhance the reduction of disease burden in psoriatic patients under methotrexate treatment? Do probiotics increase the beneficial gut bacteria and decrease the harmful gut bacteria in psoriatic patients under methotrexate treatment? Researchers will compare probiotics intake along with methotrexate to methotrexate alone to see if probiotics work to enhance the reduction of the severity of psoriasis in patients treated by methotrexate and whether the addition of probiotics will improve their gut health.\n\nParticipants will:\n\nTake a daily dose of probiotics with a weekly dose of methotrexate or only a weekly dose of methotrexate for 4 months.\n\nGive daily feedback to the researchers about their probiotic intake and their dietary intake.\n\nVisit the clinic after 1 and 2 weeks of beginning treatment and then once every 4 weeks for checkups and tests.",[25],[24,415,416,417],"gut microbiome","methotrexate","probiotics","2025-09-05",{"date":420,"type":33},"2025-09-11",{"date":422,"type":33},"2025-08-01",{"date":424,"type":20},"2026-12-30",{"name":426,"class":40},"Alexandria University",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":284,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":41},"100577709","evaluation-of-stigma-toward-patients-with-alopecia-areata-atopic-dermatitis-vitiligo-and-psoriasis-100577709","NCT06801821","Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis","STIGMADERM","Inclusion Criteria:\n\n* -Patients aged\\>18 years, both sexes;\n* Signature of written informed consent;\n\nExclusion Criteria:\n\n* Patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata.\n* Patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata\n* Those who for professional or personal reasons have direct knowledge of the diseases in question.",{"count":435,"type":20},400,"Primary objective:\n\nThe primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.\n\n* Compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.\n* Evaluate demographic factors that describe a greater tendency toward stigmatization.",[25,438,439,440],"Vitiligo Vulgaris","Atopic Dermatitis","Areata Alopecia","2025-08-25",{"date":443,"type":33},"2025-08-26",{"date":445,"type":33},"2025-02-01",{"date":447,"type":20},"2026-03-01",{"name":449,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":458,"targetDuration":460,"studyType":21,"phases":4,"briefSummary":454,"conditions":461,"keywords":464,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":41},"100603116","molecular-inflammation-board-at-the-center-for-personalized-medicine-100603116","NCT07132333","Molecular Inflammation Board at the Center for Personalized Medicine","The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study","MEB@ZPM","Inclusion Criteria:\n\n* Chronic inflammatory disorder (PsO, PsA, SpA, IBD)\n* Given informed consent\n* 18 years of age\n\nExclusion Criteria:\n\n* No capacity to consent",{"count":459,"type":20},3000,"14 Months",[25,155,462,463],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Spondylarthropathies",[465,466],"chronic inflammatory diseases","personalized medicine","2025-08-19",{"date":372,"type":33},{"date":470,"type":33},"2022-11-16",{"date":472,"type":20},"2032-11",{"name":474,"class":40},"University Hospital Tuebingen",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":284,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":485,"conditions":486,"keywords":490,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":536},"100594595","skin-disease-profiling-by-an-exploratory-prospective-biomarker-study-in-dermatology-practice-skinergy-100594595","NCT07021495","SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study for In-Depth Profiling of Patients With Chronic Immune-Mediated Inflammatory Skin Diseases in Daily Practice","SKINERGY","Inclusion Criteria:\n\nPatients:\n\n1. Able to understand and provide a written informed consent prior to any study procedures\n2. Male or non-pregnant female, ≥18 years of age\n3. Patient is willing to refrain from extensively washing (including bathing, swimming) the target lesional skin 12 hours before every study visit day.\n4. Patient is willing and able to comply with the study protocol\n5. Female participants are willing to not get pregnant between M0 until M12, from study entry to the last study visit\n6. The patient is willing to start the prescribed treatment.\n\nDisease-specific inclusion criteria\n\nFor patients with AD:\n\nTo be eligible to participate in this study, a subject must meet all of the following criteria:\n\n6\\. Diagnosis and history of chronic, moderate-to-severe AD (by the Eichenfield revised criteria of Hanifin and Rajka for at least 3 years before baseline visit.\n\n7\\. Documented recent history (last 6 months) of eligibility for (local or systemic) treatment with immunosuppressants, biologics or JAK-inhibitors.\n\n8\\. When applicable, documented recent history (last 6 months) of inadequate response to treatment with topical therapy, immunosuppressants, biologics or JAK-inhibitors.\n\n9\\. Current treatment can include moisturizers, topical treatment and\u002For systemic treatments with preferable wash-out (see exclusion criterion #9). On-study treatment is at physician and patient discretion but must include eligibility to starting new systemic treatment.\n\n10\\. EASI≥7 (moderate-to-severe disease) 11. At least one suitable target lesion at the discretion of the investigator 12. Intention to start treatment with cyclosporine A, dupilumab, tralokinumab, lebrikizumab or a JAK1-inhibitor (abrocitinib or upadacitinib)\n\nFor patients with CLE:\n\nParticipants must have a diagnosis of CLE, including SCLE, CDLE or LET that fulfil the following:\n\n6\\. Confirmed CLE diagnosis by clinicopathological correlation. 7. An overall CLE Disease Area and Severity Index Activity (CLASI-A) Score ≥3 without counting any diffuse alopecia or oral ulcers.\n\n8\\. Intention to start treatment with TCS, hydroxychloroquine or methotrexate (combination or mono-treatment).\n\nIf participating in the exploratory study with the skin biopsy: location of the lesion(s) selected for biopsy preferably outside the facial area (possible are e.g., neck, chest, back, limbs, scalp, ear etc.).\n\nFor patients with CSU:\n\n6\\. Diagnosis of CSU (moderate to severe according to international guidelines (Zuberbier et al, 2022)) for ≥3 months and symptomatic disease despite treatment with second generation H1 antihistamines (up to fourfold the approved dose).\n\n7.Patients currently on an antihistamine (up to fourfold the approved dose) must be on a stable dose for at least 2 weeks prior to day 1 and must maintain the same stable dose throughout the treatment period.\n\n8\\. Intention to start (add-on to antihistamine) treatment of omalizumab, cyclosporine A or BTK inhibitor\\*. (\\*when approved and reimbursed in NL)\n\nFor patients with HS:\n\n6\\. Patient with a history of signs and symptoms consistent with moderate-to-severe HS, based on IHS4 score (Zouboulis et al., 2017), for at least 1 year prior to baseline 7. Current treatment can include topical treatment. On-study treatment is at physician and patient discretion but must include eligibility to starting systemic treatment 8. Intention to start treatment with anti-TNF or anti-IL17 (secukinumab, bimekizumab\\*) \\*when approved and reimbursed in NL.\n\nFor patients with MF:\n\n6\\. A confirmed diagnosis of CTCL MF type and stage classification via histology or clinicopathological correlation 7. For the stage IA-IIA CTCL patients: at least one patch and\u002For one plaque lesion is present 8. Intention to start treatment with topical chlormethine, topical corticosteroids or phototherapy (PUVA \u002F UV-B).\n\nFor patients with PSO:\n\n6\\. Diagnosed with chronic plaque psoriasis at least 6 months prior to study participation 7. PASI≥5 with at least one suitable target lesion at the discretion of the investigator 8. Current treatment can include moisturizers, topical treatment and\u002For systemic treatments with preferable wash-out. On-study treatment is at physician and patient discretion but must include eligibility to starting new systemic treatment 9. Intention to start treatment with biologics: anti-TNF, anti-IL23, anti-IL17 or anti-TYK2\n\nHealthy volunteers:\n\nAll healthy volunteers must meet all of the following inclusion criteria:\n\n1. Signed informed consent before any study-mandated procedure.\n2. Male or non-pregnant female volunteers, ≥18 years of age\n3. Subject is in stable good health as per judgement of the investigator based upon the results of medical history and assessments performed at baseline.\n4. No clinically significant skin disease as judged by the investigator.\n5. No history of hypertrophic scarring or keloid.\n6. Subject is willing to refrain from extensively washing (including bathing, swimming) the skin 12 hours before every study visit.\n7. Subject is willing and able to wash out and withhold any topical treatment (prescription and over-the-counter products) in the investigational area for 2 weeks prior to Day 1.\n8. Subject is willing to refrain from application of any topical product (e.g. ointments, cream, or washing lotions) on the skin 24 hours prior to every study visit day.\n9. Subject is willing and able to wash out any antibiotic therapy for 14 days prior to Day 1.\n10. Subject is willing and able to comply with the study protocol.\n11. Female participants are willing to not get pregnant from study entry to the last study visit\n\nExclusion Criteria:\n\nPatients:\n\n1. Have any other relevant skin infection\u002Fdisease in the treatment area other than the investigated skin disease.\n2. Subjects who have received treatment with any non-marketed drug substance (that is, an agent which has not yet been made available for clinical use following registration) within 4 weeks prior to the baseline visit.\n3. Any other condition, disease, or known factor that could interfere with the study conduct or the study objectives as per judgement of the investigator. 4. Having received treatments for the investigated skin disease within the following intervals prior to the start of the study is not a strict exclusion criterion since this is a real-world study. However, preferred intervals for washout are as follows:\n\n   * 1 week for topical treatment, e.g. corticosteroids, retinoids, vitamin D analogs, calcineurin inhibitors\n   * 4 weeks for phototherapy, e.g. UVB, PUVA, PDT\n   * 4 weeks for non-biologic systemic treatment, e.g. retinoids, methotrexate, cyclosporine, JAK inhibitors\n   * 8 weeks for radiotherapy or surgery in the treatment area\n   * 8 weeks for biologics\n   * 3 months for any systemic chemotherapeutical treatment\n\nDisease specific exclusion criteria for patients with CLE:\n\n5\\. Diagnosed with SLE\n\nDisease specific exclusion criteria for patients with CSU:\n\n5\\. Treatment with omalizumab within 8 weeks prior to Day 1 6. Urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary, acquired angioedema or drug-induced (e.g., due to C1 esterase inhibitor deficiency, ACE-inhibitor induced).\n\nDisease specific exclusion criteria for patients with MF:\n\n5\\. Ongoing uncontrolled active skin infection, other than secondary impetiginized CTCL lesions as judged by the investigator\n\nDisease specific exclusion criteria for patients with PSO:\n\n5\\. Having primarily erythrodermic, pustular or guttate psoriasis; 6. Having drug-induced psoriasis;\n\nHealthy volunteers:\n\nAll healthy volunteers must meet none of the following exclusion criteria:\n\n1. History of immunological abnormality (e.g. immune suppression, severe allergy, or anaphylaxis) that may interfere with study objectives as per judgement of the investigator.\n2. History or symptoms of any uncontrolled, significant disease including (but not limited to), a neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives as per judgement of the investigator.\n3. The use of systemic antibiotic therapy for \\>2 months in the past 12 months.\n4. The use of any immunosuppressive or immunomodulatory therapy within the past 30 days prior to Day 1.\n\n6\\. Loss or donation of blood over 500mL within three months prior to baseline. Participation in an investigational drug study within 3 months prior to baseline visit or more than 4 times a year.\n\n7\\. History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months prior to baseline. Alcohol consumption will be prohibited for at least 24 hours preceding each study visit.\n\n8\\. Positive urine test for drugs or history of abuse at baseline. 9. Exposure to high doses of UV radiation is not permitted within 3 weeks of the first study visit until the end of the study 10. Extreme physical activities are not permitted within 48 hours before each study visit 11. Any other condition, disease, or known factor that could interfere with the study conduct or the study objectives as per judgement of the investigator.",{"count":484,"type":20},840,"The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers. This study is part of the larger NGID (Next Generation ImmunoDermatology) initiative, of which the main objective is to develop infrastructure that enables personalised patient care. The main questions the SKINERGY study aims to answer are:\n\n* Which biomarkers can discriminate between responders and non-responders to treatment in patients with AD, CLE, CSU, HS, MF, and PSO?\n* How do disease-related biomarkers in patients with AD, CLE, CSU, HS, MF, and PSO differ from those in healthy volunteers?\n* Which (multi-omics) biomarkers are associated with disease subtypes and predict response or non-response to (targeted) therapies in daily clinical practice?\n* How do biomarker profiles compare across different cohorts of patients with immune-mediated inflammatory skin diseases (AD, CLE, CSU, HS, MF, PSO)\n* How do biomarker levels change over time in response to treatment in these patient populations?\n* Which skin tissue biomarkers are associated with disease progression or treatment response?\n* How do the genomic profiles of patients differ across diseases or correlate with treatment outcomes?\n* Can additional imaging biomarkers enhance the characterization of disease profiles or treatment monitoring over time?\n\nResearchers will compare both differences beween patients within a disease group in different treatment arms, as well as patients within the same treatment arm. Additionally, biomarker profiles of patients with different diseases will be evaluated. These comparisons will be made to see if shared or distinct biomarker patterns exist across diseases and treatments, which could inform patient stratification, optimize therapeutic decision-making, and identify potential targets for future interventions.\n\nParticipants will start medication according to national guidelines for the treatment of their inflammatory skin disease (AD: Cyclosporin A, anti-IL4\u002F13, or anti-JAK; PSO: anti-TNF, anti-IL23, ani-IL17, anti-TYK2; HS: anti-TNF, anti-IL17; MF: CHLORM, TSC, PUVA-UV-B; CSU: anti-IgE, Cyclosporin A, anti-BTK\\*; CLE: TSC, HCQ, MTX)\n\n\\*once approved and reimbursed in the Netherlands\n\nParticipants will:\n\n* Take the prescribed medication for their skin disease (in line with standard care in the Netherlands).\n* Visit the clinic for a study visit combined with their standard care appointment 3 times (baseline, month 3, and month 6. An additional 4th visit at month 12 is optional).\n* Fill in an online set of questionnaires from home, 3 times during the study period (an additional 4th time is optional).\n* Patients with CSU fill in the UAS7 (and if applicable the AAS7) daily for the study period.",[487,488,25,104,489],"Chronic Spontaneous Urticaria (CSU)","Hidradenitis Suppurativa (HS)","CTCL\u002F Mycosis Fungoides",[491,492,493,106,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,107,515,516,517,518,519,520,521,522,523,524,525,526,527,528],"Urticaria","Hives","Mast cells","Autoallergic","Wheals","Angioedema","Abscess","Nodules","Sweat glands","Acne inversa","Eczema","Itchy, dry skin","Mycosis Fungoides","Skin patches","Tumors","T-cells","Lupus","Skin rash","Photosensitivity","Plaques","Scaling","Erythema","Induration","Inflammatory skin diseases","Deep phenotyping","Multi-omics","Transcriptomics","Lipidomics","Metabolomics","Proteomics","Genomics","Microbiomics","Imaging mass cytometry (CyTOF)","Real-world practice","Standard care","NextGenerationImmunoDermatology","NGID","Biomarkers","2025-08-18",{"date":467,"type":33},{"date":532,"type":33},"2025-07-29",{"date":84,"type":20},{"name":535,"class":40},"Leiden University Medical Center",8,{"id":538,"slug":539,"hasResults":11,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":284,"sex":544,"minAge":4,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":41},"100594304","a-study-to-assess-deucravacitinib-safety-in-pregnancy-100594304","NCT07017699","A Study to Assess Deucravacitinib Safety in Pregnancy","The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy","Inclusion Criteria:\n\nCohort 1: Deucravacitinib-exposed cohort\n\n* Currently pregnant during the enrollment period\n* Diagnosed with psoriasis (PsO) validated by medical records when possible\n* Exposure to deucravacitinib for any number of days, at any dose, and at any time from 2 days prior to date of conception (DOC) to the end of pregnancy\n* Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants\n\nCohort 2: PsO Disease-matched unexposed comparator cohort\n\n* Currently pregnant during the enrollment period\n* Diagnosed with PsO validated by medical records when possible\n* May be exposed to systemic treatments for PsO\n* Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants\n\nCohort 3: Non-disease unexposed comparator cohort\n\n* Currently pregnant during the enrollment period\n* Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants\n\nExclusion Criteria\n\nCohort 1: Deucravacitinib-exposed cohort\n\n* Pregnant women who have enrolled in this cohort study with a previous pregnancy\n* Pregnant women who have used deucravacitinib for an indication other than PsO\n* Women who do not have exposure to deucravacitinib anytime from 2 days prior to DOC to the end of pregnancy\n* Women who have exposure to another oral tyrosine kinase 2 (TYK2) inhibitor or any oral Janus kinase (JAK) inhibitor from within 5 half-lives of DOC to the end of pregnancy\n* Women who have exposure to methotrexate or an oral retinoid\n* Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)\n* Results of a diagnostic test are positive for an major congenital malformation(s) (MCM) prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM\n\nCohort 2: Disease-matched unexposed comparator cohort\n\n* Pregnant women who have enrolled in this cohort study with a previous pregnancy\n* Women who have exposure to deucravacitinib or any other oral TYK2 inhibitor except deucravacitinib, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy\n* Women who have exposure to methotrexate or an oral retinoid\n* Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)\n* Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM\n\nCohort 3: Non-disease unexposed comparator cohort\n\n* Pregnant women who have enrolled in this cohort study with a previous pregnancy\n* Women who have had exposure to deucravacitinib or any other oral TYK2 inhibitor, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy\n* Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)\n* Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM\n* Women exposed to a known, possible, or suspected human teratogen during pregnancy as confirmed by the OTIS Research Center (see Appendix 3 for list of known, possible, and suspected human teratogens)\n* Women who are diagnosed with PsO, or any other autoimmune disease","FEMALE",{"count":546,"type":20},900,"The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \\[OTIS\\]) who were exposed to deucravacitinib.",[25],[25],"2025-06-04",{"date":552,"type":33},"2025-06-12",{"date":554,"type":33},"2025-03-21",{"date":556,"type":20},"2029-02-28",{"name":558,"class":120},"Bristol-Myers Squibb",{"id":560,"slug":561,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":121},"100591966","a-prospective-study-to-assess-the-efficacy-of-il-17-inhibitors-on-subclinical-enthesitis-in-patients-with-moderate-to-severe-psoriasis-based-on-power-doppler-pd-ultrasonography-pdus-100591966","NCT06987292","A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)","Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS): a Single-center, Prospective, Exploratory, Open-label Study","Inclusion Criteria:\n\n1. Adult patients ( ≥ 18 years of age) with chronic plaque-type psoriasis\n2. Meet one of the following conditions: Psoriasis Area and Severity Index \\[PASI\\] score \\> 6, or scalp involvement, or nail involvement.\n3. Inflammatory changes on ultrasound consistent with OMERACT definition at least at one peripheral attachment point at screening, defined as thickening and\u002For abnormal echogenicity of tendons or ligaments at the site of their insertion into the bone (within 2 mm of the talar cortex), and active Doppler signals that may indicate structural damage such as bone erosion, syndesmophytes\u002Fcalcifications\n4. Psoriasis is inadequately controlled by current topical therapy or phototherapy\n5. Able to sign the informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of PsA2 according to CASPAR\n2. Any known rheumatic disease, positive rheumatoid factor\u002Fanti-citrullinated protein antibodies, prior treatment with anti-rheumatic drugs\n3. Treatment with systemic corticosteroids within 12 weeks or 5 half-lives of screening\n4. Obesity impeded ultrasound examination\n5. Pregnant or lactating women or women with plan for conception 5 months before or after treatment\n6. Participated in other clinical trials\n7. Concurrent significant medical problems, including but not limited to the following: uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 95 mmHg), congestive heart failure (NYHA class III or IV), total white blood cell count \\\u003C 2500\u002Fμl, or platelets \\\u003C 100,000\u002Fμl or neutrophils \\\u003C 1500\u002Fμl or hemoglobin \\\u003C 8.5 g\u002FdL at screening.\n8. Any liver function abnormality: aspartate aminotransferase (AST) \\> 2xULN, alanine aminotransferase (ALT) \\> 2xULN, total bilirubin (TBIL) \\> 2xULN\n9. Abnormal renal function: serum creatinine \\> 2.0 mg\u002Fdl\n10. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection, defined as a positive PPD skin test or Mycobacterium tuberculosis interferon-gamma release assay (IGRA) test.\n11. Current or relevant history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.\n12. History of lymphoproliferative disease, or any known malignancy, or history of malignancy of any organ system within the past 5 years\n13. Unable or unwilling to undergo repeated venipuncture\n14. History of alcohol or drug abuse or evidence of abuse within 6 months prior to baseline\n15. History of hypersensitivity to any component of the study drug\n16. Did not accept live vaccines within 4 weeks prior to enrollment, do not have plan of vaccination program during the study, and no live vaccines are planned \\> 6 months after the last dose of the study (herpes zoster vaccine \\> 12 months)",{"count":180,"type":20},"It is an observational, single-center, prospective, exploratory, open-label study to assess the efficacy and safety of IL-17 inhibitors on subclinical enthesitis in patients with moderate to severe psoriasis with subclinical enthesitis based on Power Doppler (PD) Ultrasonography (PDUS)",[25,569,155,570],"Enthesitis","Secukinumab","2025-05-15",{"date":573,"type":33},"2025-05-23",{"date":575,"type":33},"2025-05-01",{"date":577,"type":20},"2027-12-31",{"name":39,"class":40},{"id":580,"slug":581,"hasResults":11,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":586,"targetDuration":4,"studyType":50,"phases":588,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":41},"100588105","phase-3-effect-of-semaglutide-in-patients-with-psoriasis-and-obesity-100588105","NCT06937060","Effect of Semaglutide in Patients With Psoriasis and Obesity","SEMPSO","Inclusion Criteria:\n\n* a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent.\n* Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception\n* \\>18 years of age, up to 75 years of age\n* Adult with an initial body mass index (BMI) of 30 kg\u002Fm2 or greater (obesity) or 27 kg\u002Fm2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)\n* Moderate to severe psoriasis (PASI score 5-10= moderate, \\>10 = severe)\n* Chinese ethnicity\n* On stable dose of standard treatment\n* Ability to comply with stud\n\nExclusion Criteria:\n\n* Patients who refuse to give consent\n* Contraindication to use of GLP1 RA\n* History of pancreatitis\n* History of MEN \u002F MTC\n* Known hypersensitivity to semaglutide or excipients in semaglutide\n* Type 1 diabetes\n* Gallbladder disease\n* Active malignancy or History of malignancy within 5 years\n* Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit\n* Pregnancy or breastfeeding, subjects should inform their healthcare provider of a known or suspected pregnancy\n* History of allergic reaction assessed as related to investigational product by the investigator\n* Major psychiatric illness\n* Treatment with live\u002F attenuated vaccine within the last 28 days prior to randomisation\n* History of alcohol or substance abuse within 6 months prior to initial screening\n* Patients with a history of suicidal attempts or active suicidal ideation",{"count":587,"type":20},14,[589],"PHASE3","Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics. Weight loss can lead to reduction in psoriasis severity. Previous studies had demonstrated the efficacy of older glucagon-like peptide-1 receptor agonist (GLP1 RA) on improvement of psoriatic disease activity. Effective weight loss has been achieved by newer GLP1 RA.7 It is also known to reduce cardiovascular outcomes in patient without diabetes. Trials on the effect of semaglutide on psoriasis has not been performed except case reports.\n\nSemaglutide is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity or some adults with excess weight (overweight) who also have weight-related medical problem to help them lose weight. It contains a GLP1 RA indicated as an adjunct to diet and exercise to improve glycemic control. It has potential anti-inflammatory effects on top of weight reduction, that may lead to improvement in psoriatic disease activity.\n\nThis is an open-label, single-armed, prospective pilot trial on obese, psoriasis patients. The investigators aim to recruit 14 patients. Patients will be maintained on standard care for their psoriasis. Add-on treatment with semaglutide of up to 2.0mg per week will be administered to the intervention arm in addition to lifestyle intervention. Treatment with previous systemic immunosuppressants is allowed.\n\nThe maximum study duration for a single subject in the study will be approximately 36 weeks, 4 weeks of screening, 24-week treatment period, and a 12-week safety follow up period after the last study dose of semaglutide at week 24.",[25,592],"Obesity and Overweight",[211,213,27],"2025-05-07",{"date":596,"type":33},"2025-05-13",{"date":598,"type":33},"2025-03-20",{"date":600,"type":20},"2027-01-31",{"name":602,"class":40},"The University of Hong Kong",{"id":604,"slug":605,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":50,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":4},"100582452","phase-2-comparison-of-otezla-to-sfa-002-to-placebo-in-plaque-psoriasis-patients-100582452","NCT06863493","Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients","Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis","Inclusion Criteria:-\n\n1. Candidates for systemic therapy with mild to moderate chronic plaque psoriasis (PsO) (with or without psoriatic arthritis) at Screening and Baseline for at least 6 months prior to Baseline defined as:\n2. Body Surface Area (BSA) \\>= 10% and \\\u003C= 15%; and Psoriasis Area and Severity Index (PASI) \\>= 12; and Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0 to 4) -\n\nExclusion Criteria:\n\n1. Participant has any form of PsO other than chronic plaque PsO (e.g., pustular PsO, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO).\n2. History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.\n3. History of active ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with the assessment of PsO (e.g., hyperkeratotic eczema).\n4. Prior exposure to SFA002 or apremilast. -","85 Years",{"count":612,"type":20},125,[357,589],"The goal of this clinical trial\\] is to learn if SFA002 can treat mild, moderate and severe plaque psoriasis as good or better than Otezla, compared to placebo in adult and pediatric patients.\n\nThe main questions it aims to answer are:\n\nHow much does oral SFA002 treatment improve plaque psoriasis measured at different timepoints, 12 weeks, 24 weeks and 52 weeks of treatment.\n\nHow much does Oral Otezla (Apremilast) improve plaque psoriasis measured at different timepoints, 12 weeks, 24 weeks and 52 weeks of treatment.\n\nThese treatments will be compared to placebo, a look-alike substance that contains no drug.\n\nParticipants will be randomly placed into 3 groups to receive either SFA002, or oral apremilast or placebo for the duration of the trial. Patients that do not respond to apremilast or placebo treatment in 12 weeks will be offered the opportunity to take SFA002 for the remainder of the study.\n\nThere may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.",[25],[617,618,619],"Otezla","apremilast","Mild psoriasis","2025-03-06",{"date":622,"type":33},"2025-03-11",{"date":624,"type":20},"2025-06-01",{"date":626,"type":20},"2026-09-01",{"name":628,"class":120},"SFA Therapeutics",{"id":630,"slug":631,"hasResults":11,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":284,"sex":16,"minAge":17,"maxAge":635,"enrollmentInfo":636,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":4},"100576872","construction-of-a-psoriasis-and-psoriatic-arthritis-diagnostic-model-based-on-multidimensional-nail-information-100576872","NCT06790940","Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information","Inclusion Criteria:\n\n\\-\n\nInclusion criteria for patients with psoriasis:\n\n1. Previous or first-time diagnosis o psoriasis; if previously diagnosed, no restrictions on prior treatments;\n2. Age ≥ 18 and ≤ 80 years, with no gender restrictions;\n3. Consent to participate in this study and sign an informed consent form.\n\nInclusion criteria for non-psoriasis control subjects:\n\n(1) Patients who visit for other non-psoriasis skin conditions such as eczema or acne, and are confirmed by dermatologists not to have psoriasis; (3) Age ≥ 18 and ≤ 80 years, with no gender restrictions; (4) Consent to participate in this study and sign an informed consent form.\n\n\\-\n\nExclusion criteria for patients with psoriasis:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.\n\nExclusion criteria for non-psoriasis subjects:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.","80 Years",{"count":637,"type":20},310,"Psoriasis is a globally prevalent chronic relapsing skin disease, characterized by its long duration and tendency to relapse. In addition to skin symptoms, it can also affect nails and joints, leading to pathological features such as pitting, leukonychia, red lunula, or severe nail dystrophy. Some patients with psoriasis may develop psoriatic arthritis. Psoriatic arthritis (PsA) is a chronic relapsing musculoskeletal disease, characterized by psoriatic skin lesions accompanied by axial and peripheral joint damage, and often associated with characteristic manifestations of psoriatic nails. These nail changes typically indicate more severe disease and poorer prognosis. However, current diagnostic methods largely depend on the experience and professional knowledge of clinicians, which are subjective and uncertain. Moreover, histopathological examination is invasive and can cause additional pain and inconvenience to patients.\n\nTo develop an effective, convenient, and non-invasive early diagnostic tool for psoriasis, our research team has conducted in-depth studies in the field of psoriasis-related diagnosis and predictive models. We have successfully developed a predictive model for psoriatic arthritis, including six key predictive factors: history of joint swelling, history of arthritis, history of swelling and pain in fingers or toes, nail involvement, genital involvement, and a history of long-term local use of corticosteroids. Clinicians can effectively assess the risk of psoriatic arthritis by obtaining information about these six factors from patients. The paper \"Early detection of psoriatic arthritis in patients with psoriasis: construction of a multifactorial prediction model\" was published in Front. Immunol (DOI: 10.3389\u002Ffimmu.2024.1426127).\n\nRaman spectroscopy is a rapid, non-invasive molecular vibration detection method that has shown great potential in medical diagnostics. Studies have shown that Raman spectroscopy can distinguish normal and abnormal tissues at the molecular level and has been proven feasible in nail testing. For psoriasis, a disease that causes significant nail changes, Raman spectroscopy offers unique advantages.\n\nBased on this background, our project will conduct a prospective observational study on psoriasis and psoriatic arthritis using multidimensional nail data. We will integrate Raman spectroscopy data of nails and multidimensional clinical information and apply artificial intelligence algorithms to develop a new diagnostic tool for psoriasis and psoriatic arthritis. This tool aims to improve the accuracy and efficiency of diagnosis, providing strong support for the early detection and precise treatment of psoriasis and psoriatic arthritis.",[25,134,640,365],"Palmoplantar Pustulosis (PPP)","2025-01-23",{"date":643,"type":33},"2025-01-24",{"date":645,"type":20},"2025-01-20",{"date":647,"type":20},"2026-12-01",{"name":298,"class":40}]